N Takezako
Overview
Explore the profile of N Takezako including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton V, Kong K, et al.
Ann Oncol
. 2022 Sep;
34(3):322.
PMID: 36075840
No abstract available.
2.
Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton V, Kong K, et al.
Ann Oncol
. 2017 Sep;
28(10):2503-2510.
PMID: 28945825
Background: Most patients with multiple myeloma (MM) are considered to be incurable, and relapse owing to minimal residual disease (MRD) is the main cause of death among these patients. Therefore,...
3.
Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, et al.
Blood Cancer J
. 2015 Sep;
5:e349.
PMID: 26383822
No abstract available.
4.
Chizuka A, Kanda Y, Nannya Y, Oshima K, Kaneko M, Yamamoto R, et al.
Clin Lab Haematol
. 2002 Feb;
24(1):33-6.
PMID: 11843896
Flow cytometry (FC) is widely utilized in the diagnosis of lymphoma and the light chain ratio (LCR) is especially useful in the diagnosis of B-cell malignancy. In this study we...
5.
Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R, et al.
Ann Hematol
. 2002 Jan;
81(1):33-6.
PMID: 11807633
The range of survival duration in myeloma patients is wide and several percent of patients live longer than 10 years. Therefore, a precise prediction of survival for the individual patient...
6.
Kanda Y, Ara C, Chizuka A, Yamamoto R, Hamaki T, Suguro M, et al.
Leuk Lymphoma
. 2001 Jun;
40(3-4):351-6.
PMID: 11426557
Multiple myeloma is characterized by the accumulation of malignant plasma cells in the bone marrow and rarely cured by chemotherapy. Villunger et al. showed that the neoplastic plasma cells express...
7.
Yonemori K, Kanda Y, Yamamoto R, Hamaki T, Suguro M, Chizuka A, et al.
Leuk Lymphoma
. 2001 May;
41(5-6):607-14.
PMID: 11378578
C-reactive protein (CRP) is an acute phase reactant of inflammation. We evaluated the clinical value of serial measurement of CRP in neutropenic patients. CRP was shown to be useful to...
8.
Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, et al.
Am J Hematol
. 2001 Apr;
67(1):1-5.
PMID: 11279649
We studied clinical features and pathologic findings in 52 consecutively autopsied patients with multiple myeloma in our center between 1979 and 1998. Distant extraosseous involvement was found in 33 patients...
9.
Yamamoto R, Kanda Y, Matsuyama T, Oshima K, Nannya Y, Suguro M, et al.
Bone Marrow Transplant
. 2000 Oct;
26(6):685-8.
PMID: 11041571
Cyclophosphamide (CPA) is widely used for peripheral blood stem cell mobilization, and a dose adjustment of CPA in the presence of renal failure has not been suggested. However, we describe...
10.
Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, et al.
Cancer
. 2000 Oct;
89(7):1611-25.
PMID: 11013378
Background: Fluconazole is used widely for fungal prophylaxis. Although studies with bone marrow transplantation (BMT) recipients clearly showed the usefulness of oral fluconazole, results of the studies in neutropenic patients...